Denise Myshko

1 week ago | managedhealthcareexecutive.com | Denise Myshko

Since being named chief pharmacy officer for the University of Rochester Medical Center, effective Feb. 16, 2025, Jason R. Smith, Pharm.D., has been on a listening journey, meeting with pharmacy employees throughout the health system. His goal is to build a stronger workforce in the department of pharmacy. “Our teams were struggling with technician staffing, and that’s why I'm putting the focus on the workforce,” Smith said in an interview.

1 week ago | managedhealthcareexecutive.com | Denise Myshko

The FDA has accepted for priority review the biologics license application (BLA) for sibeprenlimab to treat patients with immunoglobulin A nephropathy (IgAN), a chronic kidney disease. Regulators have granted the BLA priority review and given sibeprenlimab a Prescription Drug User Fee Act (PDUFA) target action date of Nov. 28, 2025. If approved, sibeprenlimab would be offered as a prefilled syringe for subcutaneous injection every four weeks, intended for at-home self-administration.

2 weeks ago | managedhealthcareexecutive.com | Denise Myshko

Scientists at the National Institutes of Health (NIH) have created a set of gene delivery systems that can reach different neural cell types in the human brain and spinal cord. The new gene delivery tools can target key brain cell types, including excitatory neurons, inhibitory interneurons, striatal and cortical subtypes, brain blood vessel cells, and hard-to-reach neurons in the spinal cord.

2 weeks ago | managedhealthcareexecutive.com | Denise Myshko

The FDA has approved GSK’s Nucala (mepolizumab) as an add-on maintenance therapy for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype. COPD is a progressive inflammatory lung disease that includes chronic bronchitis and/or emphysema. It affects more than 390 million people globally and is the third leading cause of death. COPD can cause progressive airflow obstruction.

2 weeks ago | managedhealthcareexecutive.com | Denise Myshko

The FDA has approved Genentech’s Susvimo (ranibizumab) to treat patients with diabetic retinopathy (DR). This is the third FDA-approved indication for Susvimo, which is also approved for treating wet age-related macular degeneration and diabetic macular edema. Diabetic retinopathy affects almost 10 million people in the United States. It can lead to diabetic macular edema, which is a leading cause of vision loss.